Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
出版年份 2015 全文链接
标题
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
作者
关键词
-
出版物
Science Translational Medicine
Volume 7, Issue 279, Pages 279ra40-279ra40
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2015-03-19
DOI
10.1126/scitranslmed.aaa4642
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
- (2017) M. Puglisi et al. JOURNAL OF CLINICAL ONCOLOGY
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Regulating cell death at, on, and in membranes
- (2014) Xiaoke Chi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer
- (2014) A Zeuner et al. CELL DEATH AND DIFFERENTIATION
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
- (2014) S L Khaw et al. LEUKEMIA
- Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
- (2014) James M. Bogenberger et al. LEUKEMIA & LYMPHOMA
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Bcl-xL controls a switch between cell death modes during mitotic arrest
- (2014) N Bah et al. Cell Death & Disease
- Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
- (2014) Zhi-Fu Tao et al. ACS Medicinal Chemistry Letters
- Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
- (2014) T. N. Chonghaile et al. Cancer Discovery
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
- (2013) François Vaillant et al. CANCER CELL
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules
- (2013) Amrita Basu et al. CELL
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines
- (2013) N M Anderson et al. LEUKEMIA
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
- (2012) Victoria Del Gaizo Moore et al. CANCER LETTERS
- Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
- (2012) M. Wong et al. MOLECULAR CANCER THERAPEUTICS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models
- (2011) Nguyen Tan et al. CLINICAL CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
- (2011) S. R. Oakes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The BCL-2 Family Reunion
- (2010) Jerry E. Chipuk et al. MOLECULAR CELL
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started